

Fact Sheet



Company overview

GlobeImmune® is a private biopharmaceutical company developing novel treatments for infectious diseases and cancer. The Company has two products in randomized phase 2b clinical trials. GI-5005, a potential treatment for chronic hepatitis C (HCV) infection, is being developed in combination with the current standard of care - pegylated interferon and ribavirin (SOC). GI-4000, GlobeImmune's lead cancer product, is designed to treat cancers caused by mutations in a cellular protein called Ras. To date, these products have been well-tolerated, generate antigen-specific T cell immune responses and early data suggest improved clinical outcomes in patients.

GI-5005 for HCV

The GI-5005 Tarmogen contains NS3 and Core hepatitis C viral proteins, which are proteins that are highly conserved. Administration of GI-5005 generates a T cell response that recognizes and appears to eliminate cells containing these viral proteins. GI-5005 is being evaluated in a randomized Phase 2b trial comparing GI-5005 plus SOC versus SOC alone in patients chronically infected with genotype 1 hepatitis C virus. In November 2009, GlobeImmune reported positive 48 week end-of-treatment data (ETR) from this study at the AASLD annual meeting:

- ◆ GI-5005 plus SOC is well tolerated and showed comparable rates of serious adverse events and discontinuations due to adverse events compared to SOC alone
- ◆ When added to SOC, GI-5005 conferred a 15% improvement in complete virologic response (74% vs. 59%) at 48 weeks in treatment naïve patients
- ◆ In treatment naïve patients, the addition of GI-5005 to SOC resulted in a nearly 2-fold improvement in normalization of ALT, a marker of liver injury

These data suggest that GI-5005 in combination with SOC will represent a novel triple therapy approach to HCV treatment with no significant additional toxicities and a convenient monthly dosing regimen.

GI-4000

The GI-4000 Tarmogen is designed to treat cancers caused by mutations in a cellular protein called Ras. Mutations in Ras lead to uncontrolled cell division and are an underlying cause of approximately 170,000 cases of cancer in the US annually. Administration of GI-4000 generates a T cell response that appears to recognize and eliminate cells containing mutated Ras.


- ◆ GI-4000 is being evaluated in a double-blind, active-control phase 2b trial in resected pancreas cancer and an open label phase 2a trial in non-small cell lung cancer (NSCLC)
- ◆ Preliminary survival data from the adjuvant pancreas cancer study are expected to be available by the end of 2010

Corporate Highlights

- ◆ Proprietary Tarmogen® platform technology
- ◆ Two products in randomized phase 2b clinical trials
- ◆ Positive end-of-treatment HCV data for GI-5005 demonstrating a 15% absolute improvement (74% vs. 59%) in complete response over SOC alone
- ◆ Global alliance with the Celgene Corporation in oncology that includes \$40 million upfront, >\$500 million in milestone payments, plus royalties

Tarmogen Technology

Tarmogen® products are whole, heat killed recombinant *S. cerevisiae* yeast that express one or more disease-related proteins. Tarmogens are avidly taken up by antigen presenting cells, such as dendritic cells and macrophages, which then generate activated T cells capable of locating and destroying diseased cells expressing the same target protein.



Leadership

Executive Management

Timothy C. Rodell, M.D.

President & Chief Executive Officer

David Apelian, M.D., Ph.D., MBA

Chief Medical Officer

Jeffrey Rona

Chief Business Officer

John Frenz, Ph.D.

VP Operations & Manufacturing

Donald Bellgrau, Ph.D.

Founding Scientist

Richard Duke, Ph.D.

Founding Scientist

Alex Franzusoff, Ph.D.

Founding Scientist

Board of Directors

Darren Carroll

Lilly Ventures

Ralph E. Christoffersen, Ph.D.

Morgenthaler Ventures

J. William Freytag, Ph.D.

Ehud Geller, Ph.D.

Medica Venture Partners

Augustine J. Lawlor

HealthCare Ventures

Paul A. Mieyal Ph.D., CFA

Wexford Capital LLC

Dan Mitchell

Sequel Venture Partners

Timothy C. Rodell, M.D.

President & Chief Executive Officer

Investors

Adams Street Partners

Biogen-Idec, Inc.

Boston Life Science Venture

BSI Healthcapital SA (Generali)

Celgene, Inc.

China Investment & Development

Eminent Venture Capital

GC&H

Genentech, Inc.

HealthCare Ventures

Lilly Ventures

Medica Venture Partners

Mellon Family Investment Co.

Morgenthaler Ventures

PAC-LINK Bio-Venture Capital

Partners Healthcare

Sequel Venture Partners

WRF Capital

Wexford Capital

Pipeline

INFECTIOUS DISEASES		ONCOLOGY					
PRODUCT	ANTIGEN	INDICATION	RESEARCH	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
GI-5005	NS3/Core	Hepatitis C	[Progress bar from Research to Phase 2]				
Other targets		HBV, HPV, EBV, CMV, Fungal, Influenza	[Progress bar from Research to Preclinical]				
GI-4000	Mutated Ras	Resected pancreas cancer	[Progress bar from Research to Phase 2]				
		First line consolidation in NSCLC	[Progress bar from Research to Phase 1]				
		First line colorectal cancer	[Progress bar from Research to Phase 1]				
		Second line colorectal cancer	[Progress bar from Research to Phase 1]				
GI-6207	CEA	NSCLC	[Progress bar from Research to Phase 1]				
Other targets		Bcr/Abl, EGFR, Brachyury	[Progress bar from Research to Preclinical]				

Financing History

Series A: \$8 million

Led by Sequel Venture Partners
June 2003

Series B: \$38.3 million

Led by Lilly Ventures
September 2005

Series C: \$41.2 million

Led by Wexford Capital
July 2007

Series D: \$10 million

Equity component of \$40 million
upfront payment by Celgene
May 2009

Series E: \$18 million

Led by BSI Healthcapital SA / Generali
January 2010

Total Venture Financing: \$115.5 million

GlobeImmune, Inc.

1450 Infinite Dr.
Louisville, CO 80027 USA

Phone: 1-303-625-2700

Fax: 1-303-625-2710

E-mail: busdev@globeimmune.com

TARGETED MOLECULAR IMMUNOTHERAPY

